MX2024009584A - Metodos anticonceptivos con efectos de sangrado programado. - Google Patents
Metodos anticonceptivos con efectos de sangrado programado.Info
- Publication number
- MX2024009584A MX2024009584A MX2024009584A MX2024009584A MX2024009584A MX 2024009584 A MX2024009584 A MX 2024009584A MX 2024009584 A MX2024009584 A MX 2024009584A MX 2024009584 A MX2024009584 A MX 2024009584A MX 2024009584 A MX2024009584 A MX 2024009584A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- scheduled
- contraceptive methods
- scheduled bleeding
- bleeding effects
- Prior art date
Links
- 230000000740 bleeding effect Effects 0.000 title abstract 3
- 239000003433 contraceptive agent Substances 0.000 title 1
- 230000002254 contraceptive effect Effects 0.000 title 1
- AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 abstract 3
- 229950009589 estetrol Drugs 0.000 abstract 3
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 2
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 2
- 229960004845 drospirenone Drugs 0.000 abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a métodos para proporcionar anticoncepción con una mayor probabilidad de sangrado programado en una mujer con un IMC < 30.0 kg/m² y métodos para proporcionar anticoncepción con una menor probabilidad de sangrado programado en una mujer con un IMC = 30.0 kg/m². Los métodos comprenden la administración oral de una cantidad terapéuticamente efectiva de un componente de estetrol en una dosis diaria de 14 mg a 16 mg, basada en la porción de estetrol, y drospirenona en una dosis diaria de 2.5 mg a 3.5 mg. También se proporcionan composiciones que comprenden un componente de estetrol y drospirenona para su uso en dichos métodos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263308910P | 2022-02-10 | 2022-02-10 | |
| PCT/IB2023/051177 WO2023152682A1 (en) | 2022-02-10 | 2023-02-09 | Contraceptive methods with scheduled bleeding effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009584A true MX2024009584A (es) | 2024-08-14 |
Family
ID=85381439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009584A MX2024009584A (es) | 2022-02-10 | 2023-02-09 | Metodos anticonceptivos con efectos de sangrado programado. |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20250152604A1 (es) |
| MX (1) | MX2024009584A (es) |
| WO (1) | WO2023152682A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12233074B2 (en) | 2022-02-10 | 2025-02-25 | Estetra Srl | Contraceptive methods with improved pearl index |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2296943T3 (es) | 2001-05-23 | 2008-05-01 | Pantarhei Bioscience B.V. | Sistema de administracion de un medicamento estrogeno tetrahidroxilado destinado a la contracepcion hormonal. |
-
2023
- 2023-02-09 US US18/837,118 patent/US20250152604A1/en active Pending
- 2023-02-09 WO PCT/IB2023/051177 patent/WO2023152682A1/en not_active Ceased
- 2023-02-09 MX MX2024009584A patent/MX2024009584A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250152604A1 (en) | 2025-05-15 |
| WO2023152682A9 (en) | 2024-02-29 |
| WO2023152682A1 (en) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2553101T3 (es) | Precursor de esteroides sexuales en combinación con un modulador selectivo del receptor de estrógenos para la prevención y tratamiento de atrofia vaginal en mujeres postmenopáusicas | |
| EA200900491A1 (ru) | Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола | |
| BRPI0512991A (pt) | uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto | |
| PE20190739A1 (es) | Procedimiento de tratamiento de dismenorrea y dolor menstrual | |
| PT835114E (pt) | Preparado de combinacao farmaceutico kit e metodo para contracepcao hormonal | |
| MEP36008A (hr) | Farmaceutska kombinacija etinilestradiola i drospirenona za primjenu kao kontraceptivnog sredstva | |
| UY26910A1 (es) | Formulaciones de liberación sostenida para secretagogos de hormona del crecimiento | |
| PE20040157A1 (es) | Progestinas no esteroides | |
| AR121864A1 (es) | Composiciones anticonceptivas con efectos adversos reducidos | |
| Coutinho | Treatment of endometriosis with gestrinone (R-2323), a synthetic antiestrogen, antiprogesterone | |
| GEAP202215414A (en) | Contraceptive composition with reduced cardiovascular effects | |
| MX173567B (es) | Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih | |
| MX2024009584A (es) | Metodos anticonceptivos con efectos de sangrado programado. | |
| JP4908399B2 (ja) | 天然エストロゲンに基づく段階型避妊製剤 | |
| Dhont et al. | Hormonal anticonception anno 2013: a clinician’s view | |
| HRP20020258B1 (hr) | Farmaceutska kombinacija etinilestradiola i drospirenona za upotrebu kao kontracepcijskog sredstva | |
| DOP2024000021A (es) | Método para tratar la endometriosis y proporcionar una anticoncepción eficaz | |
| CL2023000450A1 (es) | Nueva composición de anticonceptivo oral de liberación modificada | |
| NO20072687L (no) | Farmasoytisk prevensjonspreparat | |
| EA200701389A1 (ru) | Твёрдая пероральная лекарственная форма для контрацепции | |
| CY1112775T1 (el) | Χρηση βαλεριανικης οιστραδιολης σε συνδυασμο με dienogest για την απο του στοματος θεραπεια της δυσλειτουργικης αιμορραγιας της μητρας σε ενοτητα με αντισυλληψη απο του στοματος | |
| UY29861A1 (es) | Uso de valerato de estradiol en combinación con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral | |
| Sturdee | Levonorgestrel intrauterine system for endometrial protection | |
| MX2024001230A (es) | Anticoncepcion oral con progestageno solo. | |
| WO2025109167A9 (en) | Combined oral contraceptive with a favorable blood pressure profile |